Remove Complication Remove Government Remove Manufacturing Remove Patients
article thumbnail

Here It Goes, Here It Goes, Here It Goes Again: The Build Back Better Act (Redux)

FDA Law

With 190 pages dedicated to prescription drug pricing reform, the program is ambitious…and complicated. As a threshold matter, the 2-year delay provision does not solve the core problem for biosimilars manufacturers: the lack of predictability that Build Back Better injects into biosimilar development.

IT 52
article thumbnail

Arsenicum album for Kerala school students: a bogus prophylaxis

Tiny Physician

The Kerala government has taken off all the restrictions imposed due to the case surge as caseload has come down, and is also planning to restart schools from the second half of November. However, there is no clinical trial on its effect on COVID 19 infection or its complications. To send a DM, use Telegram. References 1.

article thumbnail

Planning for the End of the COVID-19 Public Health Emergency

FDA Law

The President’s comments caused us, who work in the medical product industry, to wonder how the federal government officially declares an end to the Covid-19 public health emergency. But if you are a medical product manufacturer, the news of the termination of COVID-19 PHE could complicate your business plan.

Medical 98